Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicenter retrospective study (Moga-stop study).

Abstract

The results of this study suggest that progressive discontinuation of mogamulizumab (Moga) should be considered once a response is obtained in patients with Sézary syndrome, even after a short treatment duration. This may minimize the risk of adverse effects, costs and resistance to Moga. Additionally, our study emphasizes that Moga rechallenge should be encouraged as a first choice in relapsing patients.